Correction: Clusterin confers gemcitabine resistance in pancreatic cancer
نویسندگان
چکیده
Author details Surgery, the Affiliated Hospital of Medical College, QingDao University, QingDao 266003, R. P. China. Pathology, the Affiliated Hospital of Medical College, QingDao University, QingDao, Shan Dong Province 266003, P. R. China. Molecular Biology, the Affiliated Hospital of Medical College, QingDao University, QingDao, Shan Dong Province 266003, P. R. China. Hepatobiliary surgery, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China. Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. Department of Surgery, the Affiliated Hospital of Medical College, QingDao University, No 16 Jiangsu Road, Qingdao, Shan Dong Province 266003, P. R. China.
منابع مشابه
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation
OBJECTIVES To study the hypothesis that gemcitabine treatment augments the chemoresistance to gemcitabine by clusterin (sCLU) upregulation. Clusterin inhibition could augment the chemosensitivity of human pancreatic cancer cells by inhibition of clusterin-dependent pERK1/2 activation. METHODS Clusterin was silenced by serial concentration of OGX-011 transfection in pancreatic cancer MIAPaCa-2...
متن کاملClusterin confers gmcitabine resistance in pancreatic cancer
OBJECTIVE To measure clusterin expression in pancreatic cancer tissues and cell lines and to evaluate whether clusterin confers resistance to gmcitabine in pancreatic cancer cells. METHODS Immunohistochemistry for clusterin was performed on 50 primary pancreatic cancer tissues and 25 matched backgrounds, and clusterin expression in 5 pancreatic cancer cell lines was quantified by Western blot...
متن کاملpERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression
BACKGROUND Our previous study has demonstrated that knockdown of activated ERK1/2(pERK1/2) sensitizes pancreatic cancer cells to chemotherapeutic drug gemcitabine (Gem) treatment. However, the details of this survival mechanism remain undefined. It has also shown that Bcl-2 confers resistance and Bax sensitizes to gemcitabine-induced apoptosis in pancreatic cancer cells. Furthermore, the extrac...
متن کاملPlk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the mediator of gemcitabine resistance, but the molecular mechanism remains unknown. In this study, we show that Plk1 phosphorylation of Orc2 and Hbo1 mediates the resistance to ge...
متن کاملResistance in Pancreatic Cancer Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine
Although gemcitabine is the standard chemotherapeutic drug for treatment of pancreatic cancer, almost all patients eventually develop resistance to this agent. Previous studies identified Polo-like kinase 1 (Plk1) as the mediator of gemcitabine resistance, but the molecular mechanism remains unknown. In this study, we show that Plk1 phosphorylation of Orc2 andHbo1mediates the resistance to gemc...
متن کامل